News | November 10, 2022
Lupin Q2 FY2023 revenue remains flat
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
Novavax’ clinical development program reported no severe allergic reactions
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The company also raised Rs 270 crore investment from Temasek in 2019
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
Cedars-Sinai Medical Center Surgeon and Surgical Innovation Officer Dr. Jain joins the venture fund to bring clinical expertise to a portfolio of budding seed-stage healthcare companies
Subscribe To Our Newsletter & Stay Updated
